KR20150130389A - 티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법 - Google Patents
티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법 Download PDFInfo
- Publication number
- KR20150130389A KR20150130389A KR1020157027855A KR20157027855A KR20150130389A KR 20150130389 A KR20150130389 A KR 20150130389A KR 1020157027855 A KR1020157027855 A KR 1020157027855A KR 20157027855 A KR20157027855 A KR 20157027855A KR 20150130389 A KR20150130389 A KR 20150130389A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- substituted
- group
- cycloalkyl
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CC(C*(C(CC1)C2)C(*C(C=C3)=CC(C)(**)C=C3N)=O)[*@]12C(C)=C(C(*)=C(*)N1)C1=*C=C Chemical compound CC(C*(C(CC1)C2)C(*C(C=C3)=CC(C)(**)C=C3N)=O)[*@]12C(C)=C(C(*)=C(*)N1)C1=*C=C 0.000 description 11
- CAECZTJRDHCXAW-UHFFFAOYSA-N FC(Cc1cc(c(NC2CCNCC2)ncn2)c2[s]1)(F)F Chemical compound FC(Cc1cc(c(NC2CCNCC2)ncn2)c2[s]1)(F)F CAECZTJRDHCXAW-UHFFFAOYSA-N 0.000 description 2
- CAPBFJMVSAROEV-UHFFFAOYSA-N N#Cc1cc2cc(CBr)ccc2[n]1CC1CC1 Chemical compound N#Cc1cc2cc(CBr)ccc2[n]1CC1CC1 CAPBFJMVSAROEV-UHFFFAOYSA-N 0.000 description 2
- PSOJDGBGVBEYJX-UHFFFAOYSA-N N#Cc1cc2cc(CN(CC3)CCC3Nc3ncnc4c3cc(CC(F)(F)F)[s]4)ccc2[nH]1 Chemical compound N#Cc1cc2cc(CN(CC3)CCC3Nc3ncnc4c3cc(CC(F)(F)F)[s]4)ccc2[nH]1 PSOJDGBGVBEYJX-UHFFFAOYSA-N 0.000 description 2
- YWZCMFYCQOISHO-UHFFFAOYSA-N CCOC(C(C=Nc1c2cc(CC(F)(F)F)[s]1)C2=O)=O Chemical compound CCOC(C(C=Nc1c2cc(CC(F)(F)F)[s]1)C2=O)=O YWZCMFYCQOISHO-UHFFFAOYSA-N 0.000 description 1
- OBNBGPICXVQLKP-UHFFFAOYSA-N CCOC(c1cnc2[s]c(CC(F)(F)F)cc2c1NC(CC1)CCN1C(OC(C)(C)C)=O)=O Chemical compound CCOC(c1cnc2[s]c(CC(F)(F)F)cc2c1NC(CC1)CCN1C(OC(C)(C)C)=O)=O OBNBGPICXVQLKP-UHFFFAOYSA-N 0.000 description 1
- YKHRIZDMSBGNAH-UHFFFAOYSA-N COc1c(CBr)cc(cc(C#N)[nH]2)c2c1 Chemical compound COc1c(CBr)cc(cc(C#N)[nH]2)c2c1 YKHRIZDMSBGNAH-UHFFFAOYSA-N 0.000 description 1
- VNSQYSFEIBZPHF-UHFFFAOYSA-N Cc(cccc1C=O)c1OC Chemical compound Cc(cccc1C=O)c1OC VNSQYSFEIBZPHF-UHFFFAOYSA-N 0.000 description 1
- GSISCDAYSLZSLY-UHFFFAOYSA-N Cc1ccc2[nH]c(C#N)cc2c1 Chemical compound Cc1ccc2[nH]c(C#N)cc2c1 GSISCDAYSLZSLY-UHFFFAOYSA-N 0.000 description 1
- PZNHRGKPTWKGIK-UHFFFAOYSA-N Cc1ccc2[n](CC3CC3)c(C#N)cc2c1 Chemical compound Cc1ccc2[n](CC3CC3)c(C#N)cc2c1 PZNHRGKPTWKGIK-UHFFFAOYSA-N 0.000 description 1
- OWFPWALRMZBRMX-UHFFFAOYSA-N FC(Cc1cc(c(NCC2CCNCC2)ncn2)c2[s]1)(F)F Chemical compound FC(Cc1cc(c(NCC2CCNCC2)ncn2)c2[s]1)(F)F OWFPWALRMZBRMX-UHFFFAOYSA-N 0.000 description 1
- ITEDXWUEMOWJSR-UHFFFAOYSA-N N#Cc1cc(cc(CN(CC2)CCC2Nc2ncnc3c2cc(CC(F)(F)F)[s]3)cc2)c2[n]1CC1CC1 Chemical compound N#Cc1cc(cc(CN(CC2)CCC2Nc2ncnc3c2cc(CC(F)(F)F)[s]3)cc2)c2[n]1CC1CC1 ITEDXWUEMOWJSR-UHFFFAOYSA-N 0.000 description 1
- BDVCDCLETYAJAJ-UHFFFAOYSA-N NCC[n]1c2ccc(CN(CC3)CCC3Nc3ncnc4c3cc(CC(F)(F)F)[s]4)cc2cc1C#N Chemical compound NCC[n]1c2ccc(CN(CC3)CCC3Nc3ncnc4c3cc(CC(F)(F)F)[s]4)cc2cc1C#N BDVCDCLETYAJAJ-UHFFFAOYSA-N 0.000 description 1
- XDRJWUROZYDBCD-UHFFFAOYSA-N NS(c1cc(Cl)c(C=O)cc1)(=O)=O Chemical compound NS(c1cc(Cl)c(C=O)cc1)(=O)=O XDRJWUROZYDBCD-UHFFFAOYSA-N 0.000 description 1
- GVIXESHZNHTZAL-UHFFFAOYSA-N NS(c1ccc(CN2CCC(CNc3ncnc4c3cc(CC(F)(F)F)[s]4)CC2)c(Cl)c1)(=O)=O Chemical compound NS(c1ccc(CN2CCC(CNc3ncnc4c3cc(CC(F)(F)F)[s]4)CC2)c(Cl)c1)(=O)=O GVIXESHZNHTZAL-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780099P | 2013-03-13 | 2013-03-13 | |
| US61/780,099 | 2013-03-13 | ||
| PCT/US2014/022750 WO2014164543A1 (en) | 2013-03-13 | 2014-03-10 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150130389A true KR20150130389A (ko) | 2015-11-23 |
Family
ID=51529943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157027855A Withdrawn KR20150130389A (ko) | 2013-03-13 | 2014-03-10 | 티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9216993B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2968342B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2016512514A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20150130389A (cg-RX-API-DMAC7.html) |
| CN (1) | CN105188705A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014249233A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015022602A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2904612A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL241193A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2015011576A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014164543A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6535430B2 (ja) * | 2012-09-28 | 2019-06-26 | イグニタ、インク. | 非定型プロテインキナーゼcのアザキナゾリン阻害薬 |
| AU2014249233A1 (en) | 2013-03-13 | 2015-09-24 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| US10526341B2 (en) * | 2014-11-19 | 2020-01-07 | Memorial Sloan-Kettering Cancer Center | Thienopyrimidines and uses thereof |
| WO2016197027A1 (en) * | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| TWI703150B (zh) * | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制menin及mll蛋白之交互作用的方法及組合物 |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| AU2017212572A1 (en) * | 2016-01-26 | 2018-08-23 | Memorial Sloan-Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| US10752639B2 (en) | 2016-03-16 | 2020-08-25 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-MLL and methods of use |
| WO2017161028A1 (en) * | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| CN109415337B (zh) | 2016-05-02 | 2022-01-18 | 密执安大学评议会 | 作为多发性内分泌腺瘤蛋白抑制剂的哌啶 |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| ES2831084T3 (es) * | 2016-06-10 | 2021-06-07 | Vitae Pharmaceuticals Inc | Inhibidores de la interacción menina-MLL |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| AU2017326487B2 (en) | 2016-09-14 | 2021-08-05 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| CA3033239A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| TWI753016B (zh) * | 2016-09-14 | 2022-01-21 | 比利時商健生藥品公司 | Menin-mll相互作用之稠合二環抑制劑 |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| EA039109B1 (ru) * | 2016-12-07 | 2021-12-06 | Кура Онколоджи, Инк. | Мостиковые бициклические ингибиторы взаимодействия менин-mll и способы применения |
| KR102513564B1 (ko) * | 2016-12-15 | 2023-03-22 | 얀센 파마슈티카 엔.브이. | 메닌-mll 상호작용의 아제판 억제제 |
| EA201991448A1 (ru) | 2017-01-06 | 2019-12-30 | Янссен Фармацевтика Нв | Азепановые ингибиторы взаимодействия менин-mll |
| EA038388B1 (ru) * | 2017-01-16 | 2021-08-19 | Кура Онколоджи, Инк. | Замещенные ингибиторы менина-mll и способы применения |
| CN110691779B (zh) * | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
| EP3600313A4 (en) | 2017-03-31 | 2020-09-23 | The Regents of The University of Michigan | PIPERIDINES AS COVALENT MENINE INHIBITORS |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| TW201920170A (zh) * | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| JP7307729B2 (ja) * | 2017-12-20 | 2023-07-12 | ヤンセン ファーマシューティカ エヌ.ベー. | メニン-mll相互作用のエキソ-アザスピロ阻害剤 |
| CN110204552B (zh) * | 2018-02-28 | 2021-08-17 | 中国科学院上海药物研究所 | 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途 |
| CR20200464A (es) | 2018-03-08 | 2021-04-14 | Incyte Corp | Compuestos diólicos de aminopirazina como inhibidores de pi3k-y |
| CN112105621B (zh) * | 2018-03-30 | 2024-02-20 | 住友制药株式会社 | 光学活性桥型环状仲胺衍生物 |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| US12662494B2 (en) | 2018-08-08 | 2026-06-23 | Sumitomo Pharma Co., Ltd. | Optically active bridged piperidine derivative |
| EP3860978A1 (en) | 2018-10-03 | 2021-08-11 | The Regents Of The University Of Michigan | Small molecule menin inhibitors |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| CA3116141C (en) * | 2018-12-06 | 2023-09-05 | Daiichi Sankyo Company, Limited | Cycloalkane-1,3-diamine derivative |
| ES2974634T3 (es) | 2018-12-21 | 2024-06-28 | Celgene Corp | Inhibidores de tienopiridinas de RIPK2 |
| ES2991429T3 (es) * | 2019-02-01 | 2024-12-03 | Univ South Carolina | Compuestos de piridina bicíclicos para su uso en el tratamiento del cáncer |
| BR112021024108A2 (pt) | 2019-05-31 | 2022-03-22 | Ikena Oncology Inc | Inibidores de tead e usos dos mesmos |
| US11458149B1 (en) | 2019-05-31 | 2022-10-04 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
| CN112116960B (zh) * | 2019-06-20 | 2024-10-11 | 中国石油化工股份有限公司 | 柴油加氢反应的组分含量确定方法、装置 |
| TW202126636A (zh) | 2019-09-30 | 2021-07-16 | 美商阿吉歐斯製藥公司 | 作為menin抑制劑之六氫吡啶化合物 |
| MD4051678T2 (en) | 2019-10-28 | 2026-07-31 | Merck Sharp & Dohme Llc | Small molecule inhibitors of the KRAS G12C mutant |
| WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| UY38988A (es) | 2019-12-19 | 2021-06-30 | Janssen Pharmaceutica Nv | Derivados espiráncos sustituidos de cadena lineal |
| CN111297863B (zh) * | 2020-03-30 | 2021-06-25 | 四川大学华西医院 | menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用 |
| IL297039A (en) | 2020-04-07 | 2022-12-01 | Syndax Pharmaceuticals Inc | Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof |
| WO2021204159A1 (en) | 2020-04-08 | 2021-10-14 | Agios Pharmaceuticals, Inc. | Menin inhibitors and methods of use for treating cancer |
| TW202204334A (zh) | 2020-04-08 | 2022-02-01 | 美商阿吉歐斯製藥公司 | Menin抑制劑及治療癌症之使用方法 |
| WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| US12702658B2 (en) | 2020-04-24 | 2026-08-11 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C |
| AR122159A1 (es) * | 2020-05-28 | 2022-08-17 | Novartis Ag | Inhibidores de mll1 y agentes antineoplásicos |
| EP4232020A4 (en) * | 2020-10-21 | 2024-08-07 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
| WO2022109487A1 (en) | 2020-11-23 | 2022-05-27 | Merck Sharp & Dohme Corp. | Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant |
| BR112023021040A2 (pt) | 2021-05-08 | 2024-02-06 | Janssen Pharmaceutica Nv | Derivados espiro substituídos |
| EP4334310A1 (en) | 2021-05-08 | 2024-03-13 | JANSSEN Pharmaceutica NV | Substituted spiro derivatives |
| AR125866A1 (es) | 2021-05-14 | 2023-08-23 | Syndax Pharmaceuticals Inc | Inhibidores de la interacción de menina-mll |
| CA3218479A1 (en) | 2021-06-01 | 2022-12-08 | Wei Cai | Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives |
| WO2022253289A1 (en) | 2021-06-03 | 2022-12-08 | Janssen Pharmaceutica Nv | Pyridazines or 1,2,4-triazines substituted by spirocyclic amines |
| AU2022292697A1 (en) | 2021-06-17 | 2024-02-01 | Janssen Pharmaceutica Nv | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer |
| WO2023011446A1 (zh) * | 2021-08-04 | 2023-02-09 | 成都苑东生物制药股份有限公司 | 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途 |
| WO2023056589A1 (en) | 2021-10-08 | 2023-04-13 | Servier Pharmaceuticals Llc | Menin inhibitors and methods of use for treating cancer |
| US20250074910A1 (en) * | 2021-12-31 | 2025-03-06 | Hitgen Inc. | Menin inhibitor and use thereof |
| WO2023215354A1 (en) * | 2022-05-03 | 2023-11-09 | Board Of Regents, The University Of Texas System | Menin proteolysis targeting chimeras (protacs) |
| US20260151399A1 (en) | 2022-11-24 | 2026-06-04 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
| CN116199633B (zh) * | 2022-12-27 | 2024-05-31 | 甘肃省化工研究院有限责任公司 | 一种制备瑞维鲁胺的方法 |
| AR132185A1 (es) | 2023-03-24 | 2025-06-04 | Acerta Pharma Bv | COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA |
| KR20260096846A (ko) | 2023-10-20 | 2026-06-24 | 머크 샤프 앤드 돔 엘엘씨 | Kras 단백질의 소분자 억제제 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003022214A2 (en) | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| US20050222175A1 (en) * | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US7612078B2 (en) * | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| EP1947103A1 (en) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments |
| AR073739A1 (es) * | 2008-09-10 | 2010-12-01 | Kalypsys Inc | Aminopirimidinas como inhibidores de los receptores de histamina |
| WO2011014128A1 (en) * | 2009-07-30 | 2011-02-03 | National University Of Singapore | Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity |
| AU2010289321A1 (en) * | 2009-09-04 | 2012-04-05 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| GB201114212D0 (en) | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
| AU2014249233A1 (en) | 2013-03-13 | 2015-09-24 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
-
2014
- 2014-03-10 AU AU2014249233A patent/AU2014249233A1/en not_active Abandoned
- 2014-03-10 US US14/203,233 patent/US9216993B2/en active Active
- 2014-03-10 EP EP14779908.4A patent/EP2968342B1/en active Active
- 2014-03-10 WO PCT/US2014/022750 patent/WO2014164543A1/en not_active Ceased
- 2014-03-10 CA CA2904612A patent/CA2904612A1/en not_active Abandoned
- 2014-03-10 MX MX2015011576A patent/MX2015011576A/es unknown
- 2014-03-10 CN CN201480025177.5A patent/CN105188705A/zh active Pending
- 2014-03-10 JP JP2016501053A patent/JP2016512514A/ja not_active Withdrawn
- 2014-03-10 KR KR1020157027855A patent/KR20150130389A/ko not_active Withdrawn
- 2014-03-10 BR BR112015022602A patent/BR112015022602A2/pt not_active IP Right Cessation
- 2014-03-10 US US14/773,686 patent/US9505781B2/en active Active
-
2015
- 2015-09-06 IL IL241193A patent/IL241193A0/en unknown
- 2015-11-10 US US14/937,421 patent/US9505782B2/en active Active
-
2016
- 2016-10-18 US US15/296,842 patent/US10160769B2/en active Active
-
2018
- 2018-05-01 JP JP2018088243A patent/JP6670885B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL241193A0 (en) | 2015-11-30 |
| WO2014164543A1 (en) | 2014-10-09 |
| US20170253611A1 (en) | 2017-09-07 |
| JP2016512514A (ja) | 2016-04-28 |
| US9216993B2 (en) | 2015-12-22 |
| US20160137665A1 (en) | 2016-05-19 |
| EP2968342A1 (en) | 2016-01-20 |
| JP2018115214A (ja) | 2018-07-26 |
| US9505782B2 (en) | 2016-11-29 |
| BR112015022602A2 (pt) | 2017-07-18 |
| EP2968342A4 (en) | 2016-07-27 |
| EP2968342B1 (en) | 2018-10-03 |
| JP6670885B2 (ja) | 2020-03-25 |
| US9505781B2 (en) | 2016-11-29 |
| CA2904612A1 (en) | 2014-10-09 |
| US10160769B2 (en) | 2018-12-25 |
| US20140275070A1 (en) | 2014-09-18 |
| US20160046647A1 (en) | 2016-02-18 |
| AU2014249233A1 (en) | 2015-09-24 |
| MX2015011576A (es) | 2016-05-16 |
| CN105188705A (zh) | 2015-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6670885B2 (ja) | チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法 | |
| CN113874374B (zh) | 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| TWI436986B (zh) | 新穎之2環性雜環化合物 | |
| CN112739690A (zh) | 用作smarca2拮抗剂的吡啶-2-酮化合物 | |
| CN101952259B (zh) | 苯并二氮杂*化合物及药物组合物 | |
| TW202322796A (zh) | 靶向p53突變體的化合物 | |
| JP7627966B2 (ja) | Cd73阻害剤、その製造方法と応用 | |
| CN107793413A (zh) | 嘧啶杂环化合物及其制备方法和应用 | |
| WO2015127872A1 (zh) | 2,4-二取代苯-1,5-二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 | |
| JP2016041697A (ja) | キナーゼ活性の阻害剤 | |
| EP2739618A1 (en) | Quinazoline compounds as serine/threonine kinase inhibitors | |
| CN117321051A (zh) | 作为parp抑制剂的化合物 | |
| WO2022216644A1 (en) | Pyridinyl substituted oxoisoindoline compounds | |
| KR20220054307A (ko) | 암의 치료를 위한 1,2,4-옥사디아졸-5-온 유도체 | |
| CA3198096A1 (en) | Aryl derivatives for treating trpm3 mediated disorders | |
| CN114907341A (zh) | 吡啶并嘧啶酮类衍生物及其制备方法和用途 | |
| CN114206861A (zh) | 用作ripk1抑制剂的稠环杂芳基化合物 | |
| CN121517419A (zh) | 用于抑制sgk-1的吡唑并[3,4-d]嘧啶-6-基-磺酰胺衍生物 | |
| CN118434417A (zh) | 环状磺酰胺核糖核苷酸还原酶(rnr)抑制剂及其用途 | |
| JP2016113366A (ja) | アセトアミド基を有する1,2,4−トリアジン−6−カルボキサミド誘導体 | |
| JP2024540264A (ja) | ゴナドトロピン放出ホルモン拮抗剤及びその調製方法並びに使用 | |
| CN115515958A (zh) | 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途 | |
| CN120774901A (zh) | Polθ抑制剂及其药物组合物和应用 | |
| WO2025247178A1 (zh) | 一类prmt5抑制剂及其组合物和用途 | |
| TWI423974B (zh) | 三氮唑並吡啶和三氮唑並吡嗪化合物及其組合物和應用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20151007 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |